Published on 8 Sep 2022 on Zacks via Yahoo Finance

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

Article preview image

Glaukos Corporation GKOS announced positive top-line data from two pivotal studies evaluating its targeted injectable implant candidate — iDose TR — in glaucoma patients. Data from the studies showed that the slow-release iDose TR achieved excellent tolerability and a favorable safety profile. The candidate achieved non-inferior reductions in intraocular pressure (IOP) in three months from baseline compared to the timolol ophthalmic solution.

Price Performance

Shares of Glaukos rallied 18.5% on Sep 7, following the data readout. Shares of the company have gained 28.2% so far this year against the industry’s 32.4% fall and the S&P 500's 18.7% decline.

NYSE.AMN price evolution
NYSE.GKOS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Hologic (HOLX) Q1 Earnings Beat Estimates, 2023 View Up

Hologic, Inc. HOLX reported first-quarter fiscal 2023 adjusted earnings per share (EPS) of $1.07,...

Zacks via Yahoo Finance 2 Feb 2023

Edwards Lifesciences (EW) Q4 Earnings Top, Margins Increase

Edwards Lifesciences Corporation EW delivered fourth-quarter 2022 adjusted earnings per share (EP...

Zacks via Yahoo Finance 1 Feb 2023

Here's Why You Should Retain Nevro (NVRO) Stock for Now

Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and...

MSN News 31 Jan 2023

DNIF: High-Yielding Diversified Equity CEF Trading At Attractive Discount (OTCMKTS:DNIF)

DNIF recorded a high average annual return over the long run. Its currently trading at a discount...

Seeking Alpha 25 Jan 2023

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

AmerisourceBergen Corporation ABC is well-poised for growth on the back of its robust U.S. Health...

Zacks via Yahoo Finance 25 Jan 2023

Intuitive Surgical (ISRG) Falls Following Q4 Earnings Miss

Intuitive Surgical ISRG reported its fourth-quarter 2022 adjusted earnings per share (EPS) of $1....

Zacks via Yahoo Finance 25 Jan 2023

QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow

QIAGEN N.V. QGEN recently announced the launch of EZ2 Connect MDx for use in diagnostic laborator...

Zacks via Yahoo Finance 24 Jan 2023

Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe

Walgreens Boots’ WBA various strategic partnerships are expected to benefit the business over the...

Zacks via Yahoo Finance 23 Jan 2023

Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials

Charles River Laboratories International, Inc. CRL recently announced a viral vector contract dev...

Zacks via Yahoo Finance 20 Jan 2023

Charles River (CRL) to Develop RNA-based Therapy With New Pact

Charles River Laboratories International, Inc. CRL recently announced viral vector contract devel...

Zacks via Yahoo Finance 19 Jan 2023